<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03154710</url>
  </required_header>
  <id_info>
    <org_study_id>ILC-1-2016</org_study_id>
    <secondary_id>2016-A01024-47</secondary_id>
    <nct_id>NCT03154710</nct_id>
  </id_info>
  <brief_title>Relevance of a Web-mediated Follow up in Patients Having a Lymphoma With a High Risk of Relapse in Complete or Partial Response</brief_title>
  <official_title>Relevance of a Web-mediated Follow up in Patients Having a Lymphoma With a High Risk of Relapse in Complete or Partial Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weprom</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SIVAN Innovation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Weprom</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lymphoma is the 6th cancer in terms of incidence in France where approximately 11,000 new&#xD;
      cases are diagnosed each year. Most types of lymphomas occur at all ages with a predominance&#xD;
      in elderly subjects.&#xD;
&#xD;
      With the continuous improvement of the diagnostic techniques and the treatments, the&#xD;
      prognosis of lymphomas is constantly improving. However, 20-40% of patients relapse most&#xD;
      often within 2 or 3 years after the end of treatment.&#xD;
&#xD;
      The current standard follow up includes a clinical examination and a biological check-up&#xD;
      every 3 months for 2 years, then every 6 months up to 5 years and an imaging every 6 months.&#xD;
      However, the interest of this systematic surveillance by imaging is controversial.&#xD;
&#xD;
      The use of new information and communication technologies, can improve the clinical follow-up&#xD;
      of patients. To date, access to the Internet and portable technologies is sufficiently broad&#xD;
      and democratized to envisage the use of this type of remote surveillance in the field of&#xD;
      health. In particular to facilitate the dissemination of information between the patient and&#xD;
      the physician. It is thus possible to imagine using this flow of information to generate&#xD;
      alerts.&#xD;
&#xD;
      Strengthening the clinical follow-up in this indication, in which routine imaging has not&#xD;
      demonstrated their interest, in particular by the implementation of remote monitoring&#xD;
      completed by the patient, may present an advantage in terms of effectiveness and precocity of&#xD;
      care. In this pathology, up to 40% of patients relapse early (within 2 to 3 years), in the&#xD;
      vast majority of cases symptomatically (less than 2% asymptomatic relapse discovered by&#xD;
      imaging). Finally the CT scan every 6-month , which generates radiation costs and exposures&#xD;
      for a relatively low benefit, is performed in symptomatic patients since several weeks.&#xD;
&#xD;
      The aim of this study is to evaluate the interest of a web-mediated follow up using a score&#xD;
      based on the dynamics and the association of clinical and biological signs to alert the&#xD;
      physician of a possible recurrence of the patients treated for a lymphoma in complete or&#xD;
      partial response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lymphoma is the 6th cancer in terms of incidence in France where approximately 11,000 new&#xD;
      cases are diagnosed each year. Most types of lymphomas occur at all ages with a predominance&#xD;
      in elderly subjects.&#xD;
&#xD;
      With the continuous improvement of the diagnostic techniques and the treatments, the&#xD;
      prognosis of lymphomas is constantly improving. However, 20-40% of patients relapse most&#xD;
      often within 2 or 3 years after the end of treatment.&#xD;
&#xD;
      The current standard follow up includes a clinical examination and a biological check-up&#xD;
      every 3 months for 2 years, then every 6 months up to 5 years and an imaging every 6 months.&#xD;
      However, the interest of this systematic surveillance by imaging is controversial.&#xD;
&#xD;
      The use of new information and communication technologies, can improve the clinical follow-up&#xD;
      of patients. To date, access to the Internet and portable technologies is sufficiently broad&#xD;
      and democratized to envisage the use of this type of remote surveillance in the field of&#xD;
      health. In particular to facilitate the dissemination of information between the patient and&#xD;
      the physician. It is thus possible to imagine using this flow of information to generate&#xD;
      alerts.&#xD;
&#xD;
      Strengthening the clinical follow-up in this indication, in which routine imaging has not&#xD;
      demonstrated their interest, in particular by the implementation of remote monitoring&#xD;
      completed by the patient, may present an advantage in terms of effectiveness and precocity of&#xD;
      care. In this pathology, up to 40% of patients relapse early (within 2 to 3 years), in the&#xD;
      vast majority of cases symptomatically (less than 2% asymptomatic relapse discovered by&#xD;
      imaging). Finally the CT scan every 6-month , which generates radiation costs and exposures&#xD;
      for a relatively low benefit, is performed in symptomatic patients since several weeks.&#xD;
&#xD;
      In addition, strengthened clinical follow-up may improve the early detection of relapses and&#xD;
      also improve surveillance of all significant clinical complications commonly seen in patients&#xD;
      with severe disease (sepsis, thromboembolism, late iatrogenics, etc.). If a benefit in&#xD;
      survival is to be expected, it will most likely be due to the early detection of relapses and&#xD;
      better control of recidivism through early treatment and management and the early&#xD;
      implementation of appropriate supportive care, if only by the management of depressive&#xD;
      symptoms, or the management of iatrogenic or other complications.&#xD;
&#xD;
      The aim of this study is to evaluate the interest of a web-mediated follow up using a score&#xD;
      based on the dynamics and the association of clinical and biological signs to alert the&#xD;
      physician of a possible recurrence of the patients treated for a lymphoma in complete or&#xD;
      partial response.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Negative interim analysis&#xD;
  </why_stopped>
  <start_date type="Actual">July 12, 2017</start_date>
  <completion_date type="Actual">March 12, 2021</completion_date>
  <primary_completion_date type="Actual">October 14, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised, open, multicenter prospective trial</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Significant Complications Detected and Confirmed by a Medical Consultation Performed Outside the Standard Follow-up</measure>
    <time_frame>6 months</time_frame>
    <description>In the experimental group, identification of the absence of alert in case of complications and in the standard arm, identification of the absence of medical consultation (referring physician) in case of complications.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complication Detection Time</measure>
    <time_frame>24 months</time_frame>
    <description>Time between the diagnosis of a complication and the nearest expected date of the subsequent follow-up programmed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Complication Observed</measure>
    <time_frame>24 months</time_frame>
    <description>Collection of all complication presented by patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Hospitalization for Vital Emergency</measure>
    <time_frame>24 months</time_frame>
    <description>Collection of serious adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensibility of the Web-application</measure>
    <time_frame>24 months</time_frame>
    <description>Number of alerts triggered by the application in relation to the results of the systematic imaging or triggered by an alert</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance</measure>
    <time_frame>24 months</time_frame>
    <description>Number of assessement completed (usually 1 per 2 weeks) by patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performances Status (PS) at Relapse</measure>
    <time_frame>24 months</time_frame>
    <description>PS according to WHO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Completion of the quality of life questionnaire QLQ-C30 at baseline and after 3, 6, 9 and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Completion of the &quot;HUMEUR PhQ9&quot; questionnaire at baseline and after 3, 6, 9 and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction</measure>
    <time_frame>6 months</time_frame>
    <description>Completion of a questionnaire after 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>24 months</time_frame>
    <description>Time between the diagnostic of partial or complete response and the diagnostic of relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>24 months</time_frame>
    <description>Time between the diagnostic of partial or complete response and the patient's death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Lymphoma, T-Cell</condition>
  <condition>Lymphoma, Large B-Cell, Diffuse</condition>
  <condition>Lymphoma, Hodgkin</condition>
  <arm_group>
    <arm_group_label>Web-application follow up</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will have a clinical and biological exam every 3 months and a web-mediated follow up. Patients will have to connect to the MOOVCARE application every 14 days to complete a questionnaire about their symptoms. Imaging will be performed in the event of an alert or clinical problem</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will have the usual follow up (Clinical and biological exam every 3 months and imaging every 6 months)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MOOVCARE</intervention_name>
    <description>web-mediated follow up</description>
    <arm_group_label>Web-application follow up</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient with either:&#xD;
&#xD;
               1. T-cell lymphoma in first complete or partial response&#xD;
&#xD;
               2. Hodgkin lymphoma in 2nd complete or partial response including after autograft&#xD;
&#xD;
               3. Large B-cell diffuse lymphoma in 2nd complete or partial response including after&#xD;
                  autograft&#xD;
&#xD;
          2. End-of-treatment imaging in the last 4 weeks&#xD;
&#xD;
          3. Age ≥ 18 years&#xD;
&#xD;
          4. PS ≤2 (WHO)&#xD;
&#xD;
          5. Patient with an initial symptoms score less than or equal to 5&#xD;
&#xD;
          6. Patient with internet access and mailbox&#xD;
&#xD;
          7. Patient affiliated to a social security scheme&#xD;
&#xD;
          8. Patient with written consent prior to any procedure specific to the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient whose lymphoma progressed at the end of the specific treatment (evaluation &lt;3&#xD;
             months after the end of the previous treatment)&#xD;
&#xD;
          2. Symptomatic brain or meninges localisation&#xD;
&#xD;
          3. Presence or history of another cancer in the last 3 years, except skin cancers (other&#xD;
             than melanoma), in situ cancers of the cervix or other cancers considered cured&#xD;
&#xD;
          4. Persons deprived of their liberty or under trusteeship&#xD;
&#xD;
          5. Dementia, mental impairment or psychiatric pathology that may compromise the informed&#xD;
             consent of the patient and / or compliance with the protocol and follow-up of the&#xD;
             study&#xD;
&#xD;
          6. Patients who can not follow the protocol for psychological, social, family or&#xD;
             geographical reasons,&#xD;
&#xD;
          7. Pregnancy or breast-feeding&#xD;
&#xD;
          8. Patient participating in another interventional study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katell LE DU, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Jean Bernard - Le Mans</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHBA Vannes</name>
      <address>
        <city>Vannes</city>
        <state>Bretagne</state>
        <zip>56017</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <state>Gironde</state>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique du Parc</name>
      <address>
        <city>Caen</city>
        <state>Normandie</state>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut d'Hématologie de Basse Normandie</name>
      <address>
        <city>Caen</city>
        <state>Normandie</state>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé du Confluent</name>
      <address>
        <city>Nantes</city>
        <state>Pays De Loire</state>
        <zip>44277</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique Bordeaux Nord</name>
      <address>
        <city>Bordeaux</city>
        <zip>33077</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Univeritaire</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Bernard</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch Mont de Marsan</name>
      <address>
        <city>Mont-de-Marsan</city>
        <zip>40000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre d'Oncologie de Gentilly</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Anne</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 11, 2017</study_first_submitted>
  <study_first_submitted_qc>May 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2017</study_first_posted>
  <results_first_submitted>March 8, 2021</results_first_submitted>
  <results_first_submitted_qc>April 2, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 28, 2021</results_first_posted>
  <last_update_submitted>April 2, 2021</last_update_submitted>
  <last_update_submitted_qc>April 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Web-mediated follow up</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Personalized medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 17, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT03154710/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Web-application Follow up</title>
          <description>Patients will have a clinical and biological exam every 3 months and a web-mediated follow up. Patients will have to connect to the MOOVCARE application every 14 days to complete a questionnaire about their symptoms. Imaging will be performed in the event of an alert or clinical problem&#xD;
MOOVCARE: web-mediated follow up</description>
        </group>
        <group group_id="P2">
          <title>Standard</title>
          <description>Patients will have the usual follow up (Clinical and biological exam every 3 months and imaging every 6 months)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Web-application Follow up</title>
          <description>Patients will have a clinical and biological exam every 3 months and a web-mediated follow up. Patients will have to connect to the MOOVCARE application every 14 days to complete a questionnaire about their symptoms. Imaging will be performed in the event of an alert or clinical problem&#xD;
MOOVCARE: web-mediated follow up</description>
        </group>
        <group group_id="B2">
          <title>Standard</title>
          <description>Patients will have the usual follow up (Clinical and biological exam every 3 months and imaging every 6 months)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" spread="14.4"/>
                    <measurement group_id="B2" value="64" spread="12.9"/>
                    <measurement group_id="B3" value="65" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Significant Complications Detected and Confirmed by a Medical Consultation Performed Outside the Standard Follow-up</title>
        <description>In the experimental group, identification of the absence of alert in case of complications and in the standard arm, identification of the absence of medical consultation (referring physician) in case of complications.</description>
        <time_frame>6 months</time_frame>
        <population>The results presented are those of the interim analysis planned for the first 40 patients included.&#xD;
A complete analysis will be done on all the patients (52) after incrementing all the data of the patients included in a second step.</population>
        <group_list>
          <group group_id="O1">
            <title>Web-application Follow up</title>
            <description>Patients will have a clinical and biological exam every 3 months and a web-mediated follow up. Patients will have to connect to the MOOVECARE application every 14 days to complete a questionnaire about their symptoms. Imaging will be performed in the event of an alert or clinical problem&#xD;
MOOVECARE: web-mediated follow up</description>
          </group>
          <group group_id="O2">
            <title>Standard</title>
            <description>Patients will have the usual follow up (Clinical and biological exam every 3 months and imaging every 6 months)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Significant Complications Detected and Confirmed by a Medical Consultation Performed Outside the Standard Follow-up</title>
          <description>In the experimental group, identification of the absence of alert in case of complications and in the standard arm, identification of the absence of medical consultation (referring physician) in case of complications.</description>
          <population>The results presented are those of the interim analysis planned for the first 40 patients included.&#xD;
A complete analysis will be done on all the patients (52) after incrementing all the data of the patients included in a second step.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complication Detection Time</title>
        <description>Time between the diagnosis of a complication and the nearest expected date of the subsequent follow-up programmed</description>
        <time_frame>24 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Complication Observed</title>
        <description>Collection of all complication presented by patients</description>
        <time_frame>24 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Hospitalization for Vital Emergency</title>
        <description>Collection of serious adverse events</description>
        <time_frame>24 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sensibility of the Web-application</title>
        <description>Number of alerts triggered by the application in relation to the results of the systematic imaging or triggered by an alert</description>
        <time_frame>24 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compliance</title>
        <description>Number of assessement completed (usually 1 per 2 weeks) by patients</description>
        <time_frame>24 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performances Status (PS) at Relapse</title>
        <description>PS according to WHO</description>
        <time_frame>24 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life</title>
        <description>Completion of the quality of life questionnaire QLQ-C30 at baseline and after 3, 6, 9 and 12 months</description>
        <time_frame>up to 12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Depression</title>
        <description>Completion of the &quot;HUMEUR PhQ9&quot; questionnaire at baseline and after 3, 6, 9 and 12 months</description>
        <time_frame>up to 12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Satisfaction</title>
        <description>Completion of a questionnaire after 6 months</description>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival</title>
        <description>Time between the diagnostic of partial or complete response and the diagnostic of relapse</description>
        <time_frame>24 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Time between the diagnostic of partial or complete response and the patient's death</description>
        <time_frame>24 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Web-application Follow-up</title>
          <description>Patients will have a clinical and biological exam every 3 months and a web-mediated follow up. Patients will have to connect to the MOOVECARE application every 14 days to complete a questionnaire about their symptoms. Imaging will be performed in the event of an alert or clinical problem&#xD;
MOOVECARE: web-mediated follow up</description>
        </group>
        <group group_id="E2">
          <title>Standard</title>
          <description>Patients will have the usual follow up (Clinical and biological exam every 3 months and imaging every 6 months)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>falls</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>influenza A</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>endometriel carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>respiratory distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Katell LE DU</name_or_title>
      <organization>Weprom</organization>
      <phone>241682940 ext 0033</phone>
      <email>k.ledu@cjb72.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

